版本:
中国

BRIEF-Novo Nordisk: Novelion CEO leaves board to avoid potential conflict of interest

May 16 Novo Nordisk:

* Says Mary Szela steps down from Novo Nordisk's board of directors with immediate effect

* "The decision follows changed strategic focus for Novelion Therapeutics, a US-based rare disease company, where Ms Szela serves as CEO, which could lead to a potential conflict of interest" Source text for Eikon: Further company coverage: (Reporting by Stine Jacobsen)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐